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)e advent of immune checkpoint inhibitors has significantly improved the prognosis of patients with advanced malignancies. As
we begin to understand these medications, multiple immune-related adverse effects (irAEs) have been found with these drugs,
including endocrinopathies. Understanding the treatment-related adverse events of these medications is critical for clinical
practice. )yroid-related adverse effects usually occur within the first three months of treatment and rarely after eight months. It
can manifest as an early onset of thyrotoxicosis, which is largely asymptomatic, followed by a rapid transition to hypothyroidism,
requiring long-term levothyroxine substitution. We present a case in which our patient was found unresponsive, hypothermic,
and with respiratory failure almost after completing a year of treatment with pembrolizumab. He had an initial mild elevation in
thyroid-stimulating hormone (TSH) of 6.52, although with normal free thyroxine (T4) of 1.06, in his first three months of starting
treatment which then rapidly progressed to a true myxedema coma. )e infrequency with which this occurs makes it a
diagnostic challenge.
1. Introduction
Myxedema coma is defined as severe hypothyroidism leading to
decreased mental status, hypothermia, and other symptoms
related to slowing of function in multiple organs. It is a medical
emergency with high mortality rate. It is a rare presentation,
likely due to the widespread availability of TSH assays, which
allows practitioners to monitor their patients’ hormonal balance
closely. )e acuity with which this occurs, however, along with
the varied clinical presentations makes it a diagnostic challenge.
We report a case of myxedema coma in a patient who presented
at a very advanced stage while being on therapy with pem-
brolizumab. )e increased immune response induced by the
immune checkpoint inhibitors like pembrolizumab leads to
irAEs, some of which are usually irreversible.)emechanism of
thyroid-related adverse effects is still unclear and appears in-
dependent of thyroid autoantibodies but may include T cells,
natural killer cells, and/ormonocyte-mediated pathways and are
frequently associated with anti-PD1 antibodies [1–5].
2. Case Presentation
Our patient is a 70-year-old male with a history of stage IV
metastatic left lower lobe adenocarcinoma of the lung who
was on palliative pembrolizumab therapy, 200mg every
three weeks starting from October 2018. He received 200mg
intravenously over thirty minutes in normal saline at the rate
of 200ml/hr. He was followed up with his oncologist for his
thyroid function monitoring and did not have any symp-
toms of hypothyroidism at the onset of his presentation. His
time course of TSH along with free T4 is shown in Table 1.
He was admitted to the hospital after experiencing
hematemesis on 6th March 2020 for which an esoph-
agogastroduodenoscopy showed multiple esophageal ulcers
and prepyloric ulcers. His TSH was checked during that
admission and found to be 84.60. His chronic lymphedema
had worsened which was thought to be from hypo-
albuminemia. He was discharged to a nursing home on
omeprazole. Within 4 days, he was found unresponsive and
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without a pulse at the nursing home. Return of spontaneous
circulation was achieved in 10minutes, and the patient was
intubated in the field for airway protection and transferred
to our hospital’s intensive care unit with multiorgan failure.
He was found to have hypothermia, bradycardia, and severe
anasarca. Despite all aggressive measures with IV fluids,
broad-spectrum antibiotics, and dynamic support, he con-
tinued to have significant multiorgan failure, including acute
respiratory failure, circulatory failure complicated by lower
extremity deep venous thrombosis, and advanced end-stage
liver disease. He was requiring three vasopressor medica-
tions to maintain hemodynamic stability and continued to
have severe lactic acidosis with an overall grave prognosis.
His TSH at that time was found to be 171 with a free T4 of
0.38. Endocrinology was consulted, and he was diagnosed
with myxedema coma. He was immediately started on in-
travenous (IV) levothyroxine and oral liothyronine. He was
also given IV hydrocortisone to cover for adrenal insuffi-
ciency although that was thought less likely in this patient.
Given his poor outcome, multiple discussions were held with
his healthcare proxy regarding goals of care, and he was
made comfortable and terminally extubated. He was started
on lorazepam for comfort and passed away peacefully.
3. Conclusion
Myxedema coma is a rare presentation in current times
given easy accessibility of TSH testing. But the acuity of its
presentation makes it a challenge in the diagnosis and
management. We are discovering that, with patients who are
on immune checkpoint inhibitors, frequent monitoring of
thyroid functions is essential. More careful monitoring is
required when patients are experiencing illnesses that alter
their normal physiological processes (such as having an
infection and gastrointestinal bleed). Physicians should also
educate their patients about these possible adverse effects.
Endocrinopathies can often be managed by the treating
oncologist or primary care physician; however, in more
severe cases, an endocrinological evaluation and appropriate
therapy may be needed. If not promptly recognized, en-
docrine dysfunction can quickly become life-threatening in
such patients.
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Table 1: TSH and T4 values from Oct 2018 to March 2020.
Time TSH Free T4 Management
October 2018 2.21 Before starting pembrolizumab
November 2018 4.06 1.31 Not on treatment
December 2018–November 2019 1.74–3.12 Not on treatment
December 2019 6.52 1.28 Not on treatment
22nd January 2020 13.8 1.25 On levothyroxine
12th February 2020 26.50 0.99 On levothyroxine
03rd March 2020 84.60 On levothyroxine and liothyronine
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